Dergiler / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 1

Myelosuppression in Patients with Prolonged use of Piperacillin/Tazobactam

Sayfa
7–11
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Neutropenia wasdeveloped at the 4th week of the treatment in 60% of these patients.Conclusion: It should be kept in mind that myelosuppression may be encountered especially during prolonged PTZtherapy, and full blood count monitoring should be performed carefully and closely in these patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The use of piperacillin-tazobactam in hospital acquired infections requiring long treatment periods maycause adverse effects including myelosuppression.
📊
Temel Bulgular & Veri:The objective of this study was to investigatethe incidence and characteristics of myelosuppression in patients with prolonged use of piperacillin-tazobactam.Methods: Inpatients followed-up and treated in Kahramanmaras Sutcu Imam University Medical Faculty Hospital andMMT Gaziantep American Hospital between April 1, 2017 and December 31, 2018 were included in the study.
💡
Sonuç & Katkı:Neutropenia wasdeveloped at the 4th week of the treatment in 60% of these patients.Conclusion: It should be kept in mind that myelosuppression may be encountered especially during prolonged PTZtherapy, and full blood count monitoring should be performed carefully and closely in these patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:2017 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The use of piperacillin-tazobactam in hospital acquired infections requiring long treatment periods maycause adverse effects including myelosuppression. Myelosuppression results in rare, but potentially serious clinic manifestations such as neutropenia, thrombocytopenia, leukemia and anemia. The objective of this study was to investigatethe incidence and characteristics of myelosuppression in patients with prolonged use of piperacillin-tazobactam.Methods: Inpatients followed-up and treated in Kahramanmaras Sutcu Imam University Medical Faculty Hospital andMMT Gaziantep American Hospital between April 1, 2017 and December 31, 2018 were included in the study. Patients’demographic data, biochemical laboratory outcome, duration and dose of antibiotic treatment, comorbidities, sideeffects of antibiotic therapy were recorded and analyzed.Results: A total of 34 inpatients who received antibiotic therapy with piperacillin-tazobactam due to various diagnoseswere included in the study. The mean duration of PTZ use was found as 11.9±6.31 days. Of all patients, 19 (55.9%) usedantibiotics for longer than 10 days, while 15 (44.1%) used PTZ for 10 days or shorter. The mean duration of antibioticuse was found as 12.2 days in patients aged 65 years and over, while this duration was 11.5 days in patients aged under65 years. Five patients (14.7%) developed neutropenia. Neutropenia was developed in 14.8 days of PTZ treatment onaverage. The mean duration of returning to normal values was found as 1.8 days in these patients. Neutropenia wasdeveloped at the 4th week of the treatment in 60% of these patients.Conclusion: It should be kept in mind that myelosuppression may be encountered especially during prolonged PTZtherapy, and full blood count monitoring should be performed carefully and closely in these patients.

🔖

Bu Makaleye Atıf Yap

TASDOĞAN, A. M., SAHİN, A. R. (2022). Myelosuppression in Patients with Prolonged use of Piperacillin/Tazobactam. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 1, 7–11. https://ajindex.com/articles/508654

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007;5:365– 83
  2. Lee KWC, Chow KM, Chan NPH, Lo AOS, Szeto CC. Piperacillin/ tazobactam Induced myelosuppression. J Clin Med Res 2009;1:53–5
  3. Nguyen VD, Tourigny JF, Roy R, Brouillette D. Rapid-onset thrombocytopenia following piperacillin-tazobactam reexposure. Pharmacother 2015;35:e326–30
  4. Uzen G, Onem Y, Hatipoglu M, et al. Piperacillin/tazobactaminduced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection. Scand J Infect Dis 2013;45:73–6
  5. Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/ tazobactam treatment: a retrospective analysis in 38 children with cytic fibrosis. Infection 1999;27:355–6
  6. Behbahani R, Kostman JR. Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis. Ann Pharmacother 1995;29:936–7
  7. Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf 2007;30:295–306
  8. Peralta FG, Sanchez M, Roiz MP, et al. Incidence of neutropenia during treatment of bone-related infections with piperacillin- EJMI 11 tazobactam. Clin Infect Dis 2003;37:1568–72
  9. Leistner R, Sakellariou C, Gürntke S et al. Mortality and molecular epidemiology associated with extended-spectrum β-lactamase production in Escherichia coli from bloodstream infection. Infect Drug Resist 2014;7:57–62. 10. https://www.ecdc.europa.eu/sites/portal/files/documents/ Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20 FINALwith%20erratum.pdf [Access date: 15/12/2019]
  10. Armand Lefèvre L, Angebault C, Barbier F, E, et al. Emergence of imipenem resistant gram negative bacilli in intestinal flora of intensive care patients., Antimicrob Agents Chem other 2013;57:1488–95
  11. Kucers A, Crowe S, Grayson M, Hoy J. The use of antibiotics: a clinical review of antibacterial. Antifungal and Antiviral Drugs 1997:1214
  12. Weiss ME, Adkinson NF: β β-Lactam allergy. In Principles and Practice of Infectious Diseases. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia, PA: Churchill Livingston; 2000:299305
  13. Walbroehl GS, John PG. Antibiotic-associated neutropenia. Am Fam Physician 1992;45:2237–41
  14. Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics.